DV
Dividend Vision

BCLI — Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc (BCLI)

Total return is 2100.0% over the past 23.2 years, 959.3 points ahead of SPY at 1140.7%. Its deepest 1-year drawdown was 47.2%.

BCLI is an equity stock focused on Brainstorm Cell Therapeutics Inc, a biotechnology company operating in the cell therapy space. The security does not currently offer dividend distributions and carries no stated expense ratio or available asset data. This holding appeals primarily to growth-oriented investors seeking exposure to regenerative medicine and cellular therapy development rather than income-focused investors.

BCLI key facts

Asset type
Stock
Asset class
Equity
Inception date
05/28/2003
Last close
$0.99
Market cap
$9,931,297
Average volume
50800.0
Beta
0.216
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.85